Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Overview
Date Founded

2013

Headquarters

215 FIRST STREET, CAMBRIDGE, MA, 02142

Type of Company

Public

Employees (Worldwide)

866

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Sarepta Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Chief Commercial Officer & Senior Vice President

Executive Vice President & Chief Scientific Officer

Executive Vice President, Research & Development & Chief Medical Officer

Senior Vice President, GM, Head of Research & Early Development

Vice President & Corporate Controller

Executive Vice President, Technical Operations

Benefit Plan Administrator

Board of Directors

Director at Sarepta Therapeutics, Inc.

Managing Member at GSM Fund LLC

President & Chief Executive Officer at Sarepta Therapeutics, Inc.

Chairman at Karolinska Institutet

Head of Research & Development at Ovid Therapeutics, Inc.

Founder at Gray Strategic Advisors LLC

Paths to Sarepta Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Sarepta Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Sands Capital employs fundamental, bottom-up, and company-focused research in their investment process. The firm identifies and invests in high quality businesses that have the capacity to generate sustainable, above-average earnings growth over time, on a global basis. The strategies they offer are typified by deep, proprietary, business-focused global research, concentration, and a long-term investment horizon.

Details Hidden

RRAM employs a highly disciplined, proprietary investment approach which they refer to as \"Absolute Value.\" The strategy incorporates the most proven and enduring principles of value equity investing, with a specific avoidance of the pitfalls associated with the common Deep Value and Relative Value investment styles. The objective of this approach is to generate attractive, sustainable, low volatility returns over the long-term, with emphasis on minimizing downside portfolio risk. Their approach is based on four principal tenants: a focus on excellent companies trading at compelling prices, bottom-up portfolio construction, a focus on less efficient areas of the equity market, and risk aversion.

Details Hidden

AVCAP aims to achieve attractive returns with moderate risk. The firm invests primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries with a focus on publicly traded, and late-stage private biotechnology companies.

Recent Transactions
Details Hidden

Sarepta Therapeutics, Inc. issued USD Common Stock

Details Hidden

Sarepta Therapeutics, Inc. purchases Myonexus Therapeutics, Inc. from CincyTech LLC, Rev1 Ventures

Details Hidden

Sarepta Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onSarepta Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSarepta Therapeutics, Inc. issued USD Common Stock

Escrow Agent

Advised onSarepta Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onSarepta Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSarepta Therapeutics, Inc. issued USD Common Stock

Managing Director

Advised onSarepta Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Consultant

Chief Executive Officer & Director at Stoke Therapeutics, Inc.

Legal Advisor

Partner at Gibson, Dunn & Crutcher LLP

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Research at Children’s National is conducted through Children’s Research Institute (CRI), the academic arm of Children’s National Health System. Children’s Research Institute conducts and promotes translational and clinical medical research and education programs within Children’s that lead to improved understanding, prevention, treatment, and care of childhood diseases. The institute is divided into five specialty research centers: Center for Cancer and Immunology Research Center for Genetic Medicine Research Center for Neuroscience Research Center for Translational Sciences Sheikh Zayed Institute for Pediatric Surgical Innovation

Key Stats and Financials As of 2020
Market Capitalization
$6.85B
Total Enterprise Value
$12.4B
Earnings Per Share
$-7.11
Revenue
$540M
Net Profit
$-554M
Total Equity
$762M
EBITDAMargin
-97.08%
Enterprise Value / Sales
23.04x
TEVNet Income
-22.46x
Debt TEV
0.09x
EBITDA
$-524M
Total Debt
$1.09B
Three Year Compounded Annual Growth Rate Of Revenue
51.74%
Investments
Details Hidden

Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC.

Suppliers

The University of Western Australia (UWA) is a leading Australian research university and has an international reputation for excellence, innovation and enterprise. A member of the Australian 'Group of Eight' research universities, it is also among Australia's leading research universities. Sitting on the banks of the Swan River, the UWA Crawley campus is the oldest in Western Australia and among the most picturesque in the nation with its grand sandstone and terracotta buildings sitting among elegant heritage-listed gardens.

Nationwide Children's Hospital Hospitals & Patient Services | Columbus, OH

Nationwide Children's Hospital is a nationally ranked pediatric acute care teaching hospital located in the Southern Orchards neighborhood of Columbus, Ohio. The hospital has 673 pediatric beds and is affiliated with the Ohio State University College of Medicine.

BioMarin Pharmaceutical, Inc. Biotechnology | San Rafael, California

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Nippon Shinyaku Co., Ltd. Pharmaceuticals - Kyoto, Japan

Nippon Shinyaku Co., Ltd. engages in the manufacture and sale of pharmaceuticals and foodstuffs. Its operations are carried out through the following segments: Pharmaceuticals and Functional Food. The Pharmaceuticals segment develops and distributes drugs that treat urological diseases, inflammation, allergies, hematological malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders. The Functional Food segment manufactures and supplies health food ingredients, preservatives, protein preparations, nutritional ingredients, seasonings and spices, and sterilization cleaning agents. The company was founded on November 20, 1911 and is headquartered Kyoto, Japan.

Solid Biosciences, Inc. Biotechnology - Cambridge, MA

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sarepta Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sarepta Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Sarepta Therapeutics, Inc..